CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.906
AS - Asia 5.296
EU - Europa 4.709
SA - Sud America 823
Continente sconosciuto - Info sul continente non disponibili 324
AF - Africa 131
OC - Oceania 37
Totale 26.226
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.670
GB - Regno Unito 1.769
SG - Singapore 1.585
CN - Cina 1.021
IT - Italia 761
VN - Vietnam 685
HK - Hong Kong 648
BR - Brasile 638
SE - Svezia 438
BD - Bangladesh 434
FI - Finlandia 402
DE - Germania 382
FR - Francia 240
RU - Federazione Russa 207
TR - Turchia 184
ID - Indonesia 166
CA - Canada 129
IN - India 121
BG - Bulgaria 108
KR - Corea 84
IE - Irlanda 80
JP - Giappone 59
AR - Argentina 58
IQ - Iraq 48
NL - Olanda 46
MX - Messico 35
AE - Emirati Arabi Uniti 34
PK - Pakistan 33
ZA - Sudafrica 33
BE - Belgio 32
UA - Ucraina 32
AT - Austria 31
CH - Svizzera 26
TH - Thailandia 26
CL - Cile 25
EC - Ecuador 25
SA - Arabia Saudita 23
VE - Venezuela 22
ES - Italia 21
PH - Filippine 21
EG - Egitto 20
RO - Romania 20
NZ - Nuova Zelanda 19
CO - Colombia 18
JM - Giamaica 18
AU - Australia 17
PL - Polonia 17
MA - Marocco 15
MY - Malesia 15
PE - Perù 15
PT - Portogallo 14
JO - Giordania 13
CR - Costa Rica 12
CZ - Repubblica Ceca 12
KE - Kenya 12
LT - Lituania 11
PY - Paraguay 11
UZ - Uzbekistan 11
NP - Nepal 10
BZ - Belize 9
DZ - Algeria 9
NO - Norvegia 9
TN - Tunisia 9
DK - Danimarca 8
IL - Israele 8
IR - Iran 8
AZ - Azerbaigian 7
SK - Slovacchia (Repubblica Slovacca) 7
TW - Taiwan 7
BO - Bolivia 6
OM - Oman 6
PS - Palestinian Territory 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
KZ - Kazakistan 5
SN - Senegal 5
UY - Uruguay 5
BH - Bahrain 4
ET - Etiopia 4
GA - Gabon 4
HN - Honduras 4
HU - Ungheria 4
LU - Lussemburgo 4
RS - Serbia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
GR - Grecia 3
KH - Cambogia 3
LK - Sri Lanka 3
NG - Nigeria 3
NI - Nicaragua 3
PA - Panama 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
GE - Georgia 2
KG - Kirghizistan 2
Totale 25.860
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Ashburn 1.579
Santa Clara 1.372
Southend 1.304
Singapore 1.068
Woodbridge 907
Seattle 881
Houston 785
Cambridge 732
Chandler 692
Wilmington 684
Hong Kong 632
San Jose 408
Helsinki 379
Dearborn 324
Nyköping 307
Ann Arbor 300
London 300
Council Bluffs 280
Beijing 204
New York 173
Ho Chi Minh City 164
San Diego 162
Izmir 157
Dong Ket 155
Los Angeles 151
Hanoi 148
Jakarta 147
The Dalles 142
Lauterbourg 110
Sofia 106
Princeton 103
Phoenix 102
Eugene 93
Milan 93
Sunnyvale 90
Hefei 80
Chicago 79
Dublin 77
Shanghai 75
São Paulo 69
Modena 64
Buffalo 61
Munich 55
Dallas 53
Orem 53
Boardman 51
Bremen 47
Tokyo 47
Seoul 46
Redondo Beach 36
Rome 35
Frankfurt am Main 31
Atlanta 29
Redwood City 28
Bupyeong-gu 27
Toronto 26
Da Nang 24
Montreal 24
Mumbai 23
Brussels 21
Columbus 21
Nuremberg 21
Salt Lake City 21
Chennai 20
Naples 20
Norwalk 20
Amsterdam 19
Auckland 19
Bologna 19
Rio de Janeiro 19
Guangzhou 18
San Mateo 18
Baghdad 17
Haiphong 17
Johannesburg 17
Moscow 17
Paris 17
Zhengzhou 17
Belo Horizonte 16
Kunming 16
San Francisco 16
Turku 16
Brasília 15
Denver 15
Miano 15
Quito 15
Vienna 15
Falkenstein 14
Genoa 14
Springfield 14
Stockholm 14
Turin 14
Zurich 14
Portsmouth 13
Santiago 13
Amman 12
Curitiba 12
Jacksonville 12
Lima 12
Totale 19.241
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 615
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 501
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 446
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 385
Metabolic disorders across hepatocellular carcinoma in Italy 369
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 354
Immunotherapy for colorectal cancer: where are we heading? 337
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 326
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 324
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 316
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 315
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 309
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 306
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 300
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 298
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 293
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 292
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 289
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 286
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 284
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 282
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 281
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 280
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 278
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 277
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 276
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 276
Immunotherapeutic approaches for hepatocellular carcinoma 274
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 273
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 271
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 268
The Italian Rare Pancreatic Exocrine Cancer Initiative 267
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 265
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 263
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 261
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 257
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 256
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 255
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 254
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 253
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 251
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 251
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 250
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 250
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 250
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 247
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 246
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 245
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 245
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 244
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 242
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 241
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 241
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 239
Improved stool DNA integrity method for early colorectal cancer diagnosis 239
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 238
Increase of reports of suspected adverse drug reactions in oncology 237
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 233
BRAF-mutated colorectal cancer: Clinical and molecular insights 233
Sarcopenia in gastric cancer: when the loss costs too much 232
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 228
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 228
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 228
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 227
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 226
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 226
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 224
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 224
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 222
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 222
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 218
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 217
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 215
Clustered protocadherins methylation alterations in cancer 212
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 211
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 210
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 209
Hemangioblastoma of the gastrointestinal tract: A first case 209
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 208
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 201
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 198
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 195
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 192
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 191
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 186
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 184
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 183
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 183
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 181
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 177
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 173
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 165
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 164
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 164
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 162
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 162
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 156
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 155
Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma 152
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives 151
Totale 25.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.314
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.314
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.950 0 153 159 113 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20254.052 133 39 33 256 957 686 433 227 449 167 212 460
2025/20267.151 383 232 384 533 913 393 913 412 740 801 810 637
2026/2027515 303 212 0 0 0 0 0 0 0 0 0 0
Totale 26.226